MARKET

CGEN

CGEN

Compugen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.36
+0.06
+0.95%
After Hours: 6.36 0 0.00% 16:00 09/22 EDT
OPEN
6.35
PREV CLOSE
6.30
HIGH
6.48
LOW
6.26
VOLUME
388.82K
TURNOVER
--
52 WEEK HIGH
18.75
52 WEEK LOW
5.76
MARKET CAP
533.72M
P/E (TTM)
-14.8807
1D
5D
1M
3M
1Y
5Y
Compugen to Present at the Cantor Global Healthcare Conference
HOLON, , /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Cantor Global Healthcare Conference on at...
PR Newswire - PRF · 09/14 13:01
Here's Why We Think Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation Looks Fair for the time being
Performance at Compugen Ltd. ( NASDAQ:CGEN ) has been reasonably good and CEO Anat Cohen-Dayag has done a decent job of...
Simply Wall St. · 08/27 10:22
Here’s how Cathie Wood’s stocks are doing and which ones are candidates for a late-year rebound
CNBC Pro screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.
CNBC.com · 08/26 19:09
Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Morgan Stanley 19th Annual Global Healthcare Conference (virtual), o...
PR Newswire · 08/26 11:00
Compugen's Out-Licensed Lung Cancer Candidate Enters Human Trial
Benzinga · 08/19 13:58
BRIEF-Compugen Announces Lung Cancer Treatment To Enter Phase 1/2 Study
reuters.com · 08/19 11:47
Compugen Announces Bispecific Antibody Derived From COM902 To Enter Clinical Development
Compugen Ltd. (NASDAQ:CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that a bispecific antibody of AstraZeneca derived from COM902,
Benzinga · 08/19 11:09
MFIN, HARP, MRIN and ERYP among after hours movers
Gainers: MFIN +6.1%. HARP +4.7%. CEVA +4.1%. SYRS +3.9%. CGEN +3.1%. Losers: MRIN -12.7%. ERYP -8.1%. AMTX -8.0%. MRKR -3.8%. TRUP -3.5%.
Seekingalpha · 07/30 21:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CGEN. Analyze the recent business situations of Compugen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CGEN stock price target is 20.86 with a high estimate of 28.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 127
Institutional Holdings: 37.03M
% Owned: 44.12%
Shares Outstanding: 83.92M
TypeInstitutionsShares
Increased
33
2.21M
New
20
301.48K
Decreased
33
4.04M
Sold Out
21
1.59M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.30%
Pharmaceuticals & Medical Research
-0.11%
Key Executives
Chairman/Director
Paul Sekhri
President/Chief Executive Officer/Director
Anat Cohen-Dayag
Chief Financial Officer
Ari Krashin
Vice President
Zurit Levine
Vice President - Research & Development
John Hunter
Other
Henry Adewoye
Director
Jean-Pierre Bizzari
Director
Gilead Halevy
Director
Kinneret Livnat Savitsky
Director
Eran Perry
Director
Michal Preminger
Director
Sanford Zweifach
Independent Director
Yair Aharonowitz
Independent Director
Ruth Arnon
Independent Director
Arie Ovadia
No Data
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Webull offers kinds of Compugen Ltd. (USA) stock information, including NASDAQ:CGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CGEN stock methods without spending real money on the virtual paper trading platform.